Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

\

GeneTether Therapeutics Inc. (C:GTTX)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for GTTX within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Aug 26, 2022 14:40 ET
The Power Play by The Market Herald Releases New Interviews with Datametrex, Cloud DX, Alkaline, and GeneTether Therapeutics
VANCOUVER, BC / ACCESSWIRE / August 26, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Datametrex, Cloud DX, Alkaline, and GeneTether Therapeutics on their latest news.
Read full article
Aug 25, 2022 10:20 ET
GeneTether Therapeutics Inc. Announces Second Quarter 2022 Financial Results and Reports on Corporate Highlights
Vancouver, British Columbia – TheNewswire - August 24, 2022 – GeneTether Therapeutics Inc. (“GeneTether” or the “Company”) (CSE:GTTX), (CNSX:GTTX.CN), announced today the filing of its interim condensed consolidated financial statements for the period ending June 30, 2022 and reported on corporate highlights for the second quarter of fiscal 2022. GeneTether is an early-stage genetic medicine company focused on developing its disruptive proprietary GeneTether™ platform technology, which is designed to significantly increase the efficiency of DNA insertion into the genome. All dollar amounts ar
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
7.58
4.54
Price to Book - most recent quarter
3.10
2.51
1.83
Price to Cash Flow per share - TTM
--
13.86
10.24
Price to Free Cash Flow per share - TTM
--
14.88
15.03
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Sep 15, 2022440-1,560
Aug 31, 20222,0001,600
Aug 15, 20224000
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

GeneTether Therapeutics Inc. is a Canada-based genetic medicines company. The Company is focused on creating gene editing therapies based on its GeneTether platform. It is engaged in building a discovery pipeline focused on the treatment of rare, monogenic diseases of the kidney and the skin. Its GeneTether platform also allows for high fidelity engineering of cells to permanently deliver the therapeutic proteins necessary to treat certain genetic diseases. Its GeneTether platform has the potential to significantly improve upon current gene editing methods by actively positioning reparative DNA fragments, which are referred to as donor DNA templates. By positioning a donor DNA template directly at the site of a double strand break, the GeneTether platform drives the DNA repair process towards homology-directed repair (HDR). Its platform is designed to enhance the efficiency of genome editing technologies, including CRISPR-Cas, TALENs, and ZFNs.

See business summary

 

Twitter

Search (past week) for $GTTX.CA

  • No tweets found